How to Outsource CMC and Control Strategy for Biologics Without Losing Control

Biologics regulation, including the management of Chemistry, Manufacturing, and Controls (CMC) and control strategy, is a critical aspect of ensuring compliance with regulatory expectations in the US, UK, and EU. As companies navigate the complexities of biologics development, outsourcing CMC activities can offer significant benefits. However, to retain regulatory compliance and minimize approval delays, it is essential to maintain control throughout the outsourcing process. This article provides a structured explanation of relevant regulations, guidelines, and agency expectations regarding the outsourcing of CMC and control strategy for biologics, emphasizing key decision points and best practices.

Context

Biologics, including monoclonal antibodies, vaccines, and cell-based therapies, are products derived from living organisms. The development and manufacturing of these products are subject to rigorous regulatory scrutiny. CMC encompasses the design, development, and verification of the manufacturing process capability to ensure that the biologics produced are of high quality, safe, and effective. The regulatory landscape for biologics is guided by various regulations and guidelines, including:

• FDA Guidance Documents
• EMA Guidelines
• ICH Quality Guidelines

To ensure compliance, it is vital for teams involved in Regulatory Affairs (RA) to understand the overarching regulatory requirements and the implications of outsourcing CMC activities.

Legal/Regulatory Basis

The regulatory framework governing biologics varies across jurisdictions but remains largely consistent in its core principles. In the US, biologics are regulated under the Public Health Service Act (PHSA) and the Federal Food, Drug, and Cosmetic Act (FDCA). In the EU, Regulation (EC) No 726/2004 lays out the procedures for the authorization and supervision of medicinal products for human and veterinary use. In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) oversees the regulation under the Human Medicines Regulations 2012.

Key regulatory requirements include:

• Good Manufacturing Practice (GMP): Compliance with GMP is essential to ensure that products are consistently produced and controlled according to quality standards.
• Quality by Design (QbD): ICH Q8 emphasizes the need to understand the product and its manufacturing process to ensure consistent quality.
• Validation and Verification: According to ICH Q9, a comprehensive risk assessment and understanding of critical quality attributes (CQAs) are necessary for effective control strategies.

Documentation

Maintaining comprehensive and accurate documentation is crucial when outsourcing CMC activities. The following documentation should be prioritized:

• Quality Agreements: Draft a Quality Agreement that outlines the responsibilities of both parties with respect to CMC activities. This should include aspects like GMP compliance, change control procedures, and audit rights.
• Master Production and Control Records: Document all processes involved in the manufacturing of the biologic, including the specifications, procedures, and controls.
• Change Control Documentation: Establish a robust change control process to ensure any modifications to the manufacturing process, materials, or suppliers are adequately evaluated and documented.

Each document must be readily accessible and reflect real-time updates as activities progress. This transparency is key to passing regulatory inspections.

Review/Approval Flow

Outsourcing CMC activities introduces additional review and approval steps that need to be integrated into the regulatory submission strategy. The following flow outlines the essential stages:

1. Initial Assessment and Selection: Evaluate potential Contract Manufacturing Organizations (CMOs) based on their experience, compliance history, and capacity for meeting CMC needs.
2. Contract Negotiation and Quality Agreement: Draft and negotiate the Quality Agreement to ensure alignment on quality expectations and contractual obligations.
3. Documentation and Process Transfer: Facilitate knowledge transfer and ensure that all relevant documentation, including standard operating procedures (SOPs), is available.
4. Pre-Approval Inspection (PAI): Prepare for regulatory inspections that may evaluate the CMOs’ compliance with GMP. An internal audit of the CMO prior to the submission can help in identifying potential issues.
5. Submission Preparation: Gather all necessary data to support the regulatory submission, including process validation data, stability data, and release criteria.
6. Regulatory Authority Review: Submit the application to the regulatory authority (FDA, EMA, or MHRA) for approval, addressing any questions or deficiencies during the review period.

Common Deficiencies

Understanding common regulatory deficiencies can help organizations avoid approval delays. Frequent questions from agencies during the evaluation process include:

• Inadequate Process Validation: Regulatory authorities often express concerns if validation data is insufficient to demonstrate that the processes can consistently produce a product meeting its pre-defined specifications.
• Insufficient Stability Data: Failure to provide comprehensive stability data to support shelf-life claims and storage conditions can lead to delays in approval.
• Inconsistent Quality Control: Lack of clear documentation related to the Quality Control (QC) measures can raise red flags during inspections.

RA-Specific Decision Points

When to File as Variation vs. New Application

One of the fundamental decisions in CMC management is determining when to submit variations versus new applications. The following guidelines can aid in making this decision:

• A **variation** is generally required when there are changes to the manufacturing process that do not affect the product’s quality or therapeutic outcome.
• A **new application** might be necessary if there are significant changes, such as a new site of manufacture or if a new active ingredient is introduced.
• Always assess the potential impact of the change on the product’s quality, efficacy, and safety profile, which will guide whether to proceed with a variation or a new application.

Justifying Bridging Data

In cases where there is a concern over data continuity—such as changes in the manufacturing process or supplier—a justification for bridging data must be established. Effective justifications should include:

• Data Integrity: Provide a clear explanation of how the quality of the biologic has been maintained despite changes.
• Comparative Analysis: Use comparative studies to showcase that the product maintains similar quality attributes and performance as prior versions.
• Regulatory Precedents: Reference previous decisions by regulatory authorities where similar justifications were accepted, if applicable.

Maintaining an organized and proactive approach to regulatory compliance in outsourced CMC activities helps organizations mitigate risks associated with biologics regulation. Emphasizing communication and documentation integrity among stakeholders can facilitate a more streamlined regulatory process and enhance inspection readiness.

Conclusion

Successfully outsourcing CMC and control strategy for biologics requires a comprehensive understanding of regulatory requirements and best practices. By adhering to the principles set forth by regulatory authorities and maintaining control throughout the outsourcing process, companies can minimize risks associated with biologics regulation while ensuring compliance with CMC requirements. This methodical approach not only improves the likelihood of successful regulatory submissions but also strengthens overall product quality and safety.